Current situation of clinical research of buccal mucosa squamous cell carcinoma
Liu Xiaoyang, Liu Xuewen, Wang Hui
Department of Radiation Oncology,Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine,Key Laboratory of Translational Radiation Oncology,Changsha 410013,China
Abstract：Treatment approaches for buccal mucosa carcinoma include surgery,radiotherapy,chemotherapy,targeted therapy,immunotherapy and various combinations of these modalities, whereas the clinical efficacy is not satisfactory. In this article, literature review was conducted to summarize the current situation of the diagnosis,lymph node metastasis,treatments of buccal mucosa carcinoma, aiming to provide reference for clinical practice.
Liu Xiaoyang,Liu Xuewen,Wang Hui. Current situation of clinical research of buccal mucosa squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2020, 29(4): 304-307.
[1] Adel M,Kao HK,Hsu CL,et al. Evaluation of lymphatic and vascular invasion in relation to clinicopathological factors and treatment outcome in oral cavity squamous cell carcinoma[J]. Medicine,2015,94(43):e1510. DOI:10.1097/md.0000000000001510.
[2] Sagheb K,Blatt S,Kraft IS,et al. Outcome and cervical metastatic spread of squamous cell cancer of the buccal mucosa,a retrospective analysis of the past 25 years[J]. J Oral Pathol Med,2017,46(6):460-464. DOI:10.1111/jop.12537.
[3] Rahmi A,Ishak Abduk R,Bastaman B,et al. Tobacco (kretek) smoking,betel quid chewing and risk of oral cancer in a selected Jakarta population[J]. Asian Pac J Cancer Prev,2014,15(20):8673-8678. DOI:10.7314/APJCP.2014.15.20.8673.
[4] Li XN,Feng Z,Jian NL,et al. Prognostic factors of squamous cell carcinoma of the buccal mucosa:a retrospective study of 168 cases in north China[J]. J Oral Maxillofac Surg,2014,72(11):2344-2350.
[5] Zelefsky MJ,Harrison LB,Fass DE,et al. Postoperative radiotherapy for oral cavity cancers:Impact of anatomic subsite on treatment outcome[J]. Head Neck,2010,12(6):470-475. DOI:10.1016/S0901-5027(05)80189-4.
[6] 史潇,嵇庆海. 头颈部鳞癌TNM分期的进展与展望[J]. 中国癌症杂志,2017,27(6):510-515. DOI:10.19401/j.cnki.1007-3639.2017.06.019.
Shi X,Ji QH. Progress and prospect of TNM staging system of head and neck squamous cell carcinoma[J]. China Oncol,2017,27(6):510-515. DOI:10.19401/j.cnki.1007-3639.2017.06.019.
[7] Liao CT, Chang JT, Wang HM,et al. Surgical outcome of T4a and resected T4b oral cavity cancer[J]. Cancer,2006,107(2):337-344. DOI:10.1002/cncr.21984.
[8] Liao CT,Wen YW,Yang LY,et al. Comparative clinical outcomes of Taiwanese patients with resected buccal and tongue squamous cell carcinomas[J]. Oral Oncol,2017,67(1):95-102. DOI:10.1016/j.oraloncology.2017.02.011.
[9] Mair MD,Nair S,Nikam S,et al. Longitudinal and cross-sectional assessment of quality of life in surgically treated advanced (T4) cancer of the buccal mucosa[J]. Oral Surg Oral Med Oral Pathol Oral Radiol,2017,124(6):529-536.
[10] Mair MD,Sawarkar N,Nikam S,et al. Impact of radical treatments on survival in locally advanced T4a and T4b buccal mucosa cancers:selected surgically treated T4b cancers have similar control rates as T4a[J]. Oral Oncol,2018,82(1):17-22.
[11] Martinez-Lara I,Fernandez-Solis J,Julia-Martinez M,et al. Behavior of buccal mucosal squamous cell carcinoma:a retrospective study of 53 carcinomas of this anatomical region[J]. Craniomaxillofac Trauma Reconstr,2018,12(1):8-13. DOI:10.1055/s-0038-1668583.
[12] Patel SG,Amit M,Yen TC,et al. Lymph node density in oral cavity cancer:results of the International Consortium for Outcomes Research[J]. Br J Cancer,2013,109(8):2087-2095. DOI:10.1038/bjc.2013.570.
[13] Xing Y,Zhang J,Lin H,et al. Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma[J]. Cancer,2016,122(4):534-545. DOI:10.1002/cncr.29780.
[14] Kowalski LP,Bagietto R,Lara JR,et al. Prognostic significance of the distribution of neck node metastasis from oral carcinoma[J]. Head Neck,2015,22(3):207-214. DOI:10.1002/(SICI)1097-0347(200005)22:3<207::AID-HED1>3.0. CO;2-9.
[15] 詹世斌,周晓.cN0期口腔癌颈淋巴清扫及方式选择的争议[J]. 临床口腔医学杂志,2018,34(1):57-60. DOI:10.3969/j.issn.1003-1634.2018.01.018.
Zhan SB,Zhou X. The controversy of neck dissection and method selection for cN0 oral cavity cancer[J]. J Clin Stomatol,2018,34(1):57-60. DOI:10.3969/j.issn.1003-1634.2018.01.018.
[16] D′Cruz A,Dandekar M,Vaish R,et al. Elective versus therapeutic neck dissection in the clinically node negative early oral cancer:A randomised control trial (RCT)[J]. J Clin Oncol,2015,33(18 Suppl):LBA3.
[17] Ren ZH,Xu JL,Li B,et al. Elective versus therapeutic neck dissection in node-negative oral cancer:Evidence from five randomized controlled trials[J]. Oral Oncol,2015,51(11):976-981. DOI:10.1016/j.oraloncology.2015.08.009.
[18] 张继青,钟雷,李金娥,等. 不同治疗方式对颊黏膜鳞状细胞癌的疗效分析[J]. 华南国防医学杂志,2017,31(6):380-382.
Zhang JQ,Zhong L,Li JE, et al. Effect analysis of different treatments for patients with buccal mucosa squamous-cell carcinoma[J]. Mil Med J Sout Chin,2017,31(6):380-382.
[19] Chun-Shu L,Yee-Min J,Ming-Fang C,et al. Squamous cell carcinoma of the buccal mucosa:an aggressive cancer requiring multimodality treatment[J]. Head Neck,2010,28(2):150-157. DOI:10.1002/hed.20303.
[20] Diaz EM, Holsinger C, Zuniga ER,et al. Squamous cell carcinoma of the buccal mucosa:one institution′s experience with 119 previously untreated patients[J]. Head Neck,2003,25(4):267-273. DOI:10.1002/hed.10221.
[21] Nair MK,Sankaranarayanan R,Padmanabhan TK. Evaluation of the role of radiotherapy in the management of carcinoma of the buccal mucosa[J]. Cancer,1988,61(7):1326-1331.
[22] Gau M,Karabajakian A,Reverdy T,et al. Induction chemotherapy in head and neck cancers:Results and controversies[J]. Oral Oncol,2019,95:164-169. DOI:10.1016/j.oraloncology,2019.06.015.
[23] Lorch JH,Goloubeva O,Haddad RI,et al. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck:long-term results of the TAX 324 randomised phase 3 trial[J]. Lancet Oncol,2011,12(2):153-159. DOI:10.1016/S1470-2045(10)70279-5.
[24] Trotti A. Principles and practice of radiation oncology,third edition[J]. Head Neck,2015,20(8):763-763. DOI:10.1097/00000421-199206000-00020.
[25] Lubek JE,Dyalram D,Liu X,et al. A Retrospective analysis of squamous carcinoma of the buccal mucosa:an aggressive subsite within the oral cavity[J]. J Oral Maxillofac Surg,2013,71(6):1126-1131. DOI:10.1016/j.joms.2012.12.006.
[26] Fang FM,Leung SW,Huang CC,et al. Combined-modality therapy for squamous carcinoma of the buccal mucosa:treatment results and prognostic factors[J]. Head Neck,2015,19(6):506-512. DOI:10.1002/(SICI)1097-0347(199709)19:63.0. CO;2-2.
[27] Dixit S,Vyas RK,Toparani RB,et al. Surgery versus surgery and postoperative radiotherapy in squamous cell carcinoma of the buccal mucosa:a comparative study[J]. Ann Surg Oncol,1998,5(6):502-510. DOI:10.1007/BF02303642.
[28] Bernier J. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J]. N Engl J Med,2005,9(2):133-134. DOI:10.1016/j.canrad.2005.02.001.
[29] Cooper JS,Pajak TF,Forastiere AA,et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J]. N Engl J Med,2004,350(19):1937-1944. DOI:10.1056/NEJMoa032646.
[30] Patil VM,Prabhash K,Noronha V,et al. Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers[J]. Oral Oncol,2014,50(10):1000-1004. DOI:10.1016/j.oraloncology,2014.07.015.
[31] Vermorken JB,Ricard M,Fernando R,et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med,2009,359(11):1116-1127. DOI:10.1056/NEJMoa0802656.
[32] Stewart JSW,Cohen EEW,Lisa L,et al. Phase Ⅲ study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck[J]. J Clin Oncol,2009,27(11):1864-1871. DOI:10.1200/JCO.2008.17.0530.
[33] Soulières D,Faivre S,Mesía R,et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1):a randomised,double-blind,placebo-controlled phase 2 trial[J]. Lancet Oncol,2017,18(3):323-335. DOI:10.1016/S1470-2045(17)30064-5.
[34] Harrington-Kevin J,Ferris-Robert L. Nivolumab versus standard,single-agent therapy of investigator′s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141):health-related quality-of-life results from a randomised,phase 3 trial[J]. Lancet Oncol,2017,18(8):S1470204517304217. DOI:10.1016/S1470-2045(17)30421-7.
[35] Cohen EEW,Soulières D,Le Tourneau C,et al. Pembrolizumab versus methotrexate,docetaxel,or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040):a randomised,open-label,phase 3 study[J]. Lancet,2019,393(10167):156. DOI:10.1016/S0140-6736(18)31999-8.
2020, Vol. 29 
